Does fondaparinux improve ischemic events, bleeding, and mortality compared to enoxaparin in patients with acute coronary syndromes?
In patients with acute coronary syndromes, fondaparinux offers similar short-term ischemic protection to enoxaparin but with significantly less major bleeding and improved long-term mortality.
Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. (ClinicalTrials.gov number, NCT00139815.).
Salim Yusuf (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: